Therapy Areas: AIDS & HIV
ALK-Abelló appoints new CFO
6 November 2017 -

ALK-Abelló A/S (CPH:ALKB:DC), a research-driven pharmaceutical company focused on allergy prevention, diagnosis and treatment, announced on Friday that it has appointed Søren Jelert as its new chief financial officer (CFO) and executive vice president.

In his new role, Jelert will report directly to Carsten Hellmann. He is expected to take up his new role by 2 January 2018.

Jelert succeeds Flemming Pedersen, who will be leaving the company.

Most recently, since 2016, Jelert has been general manager of NNE's US organisation. Prior to that, from 2008 until 2016, he was CFO at NNE. Before that, his experience includes various finance roles at Novo Nordisk and Maersk.

Login
Username:

Password: